Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease
Conditions
Interventions
Obinutuzumab
Locations
4
China
Beijing, China
Beijing, China
Guangzhou, China
Shanghai, China
Start Date
September 1, 2012
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
April 25, 2016
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions